Publications

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.  2018.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.. Cancer Discov. 8(3):354-369.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.  2018.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.. Cancer Discov. 8(3):354-369.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, R Karnes J, Ross AE, Schaeffer EM, Rubin MA et al..  2018.  Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.. JCO Precis Oncol. 2018

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes J, Ross AE, Schaeffer EM, Rubin MA et al..  2018.  Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y et al..  2019.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. Cancer Cell. 35(4):603-617.e8.

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al..  2019.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al..  2019.  Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.

Beltran H, Nanus DM, Sboner A, Mosquera JMiguel, Elemento O, Tagawa ST, Demichelis F, Romanel A, Conteduca V, Casiraghi N et al..  2020.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.

Kolin DA, Kulm S, Elemento O.  2020.  Clinical and Genetic Characteristics of Covid-19 Patients from UK Biobank.. medRxiv.

Liu D, Barbieri CE, Rubin MA, Demichelis F, Mosquera JMiguel, Elemento O, Sboner A, Shoag JE, Poliak D, Goueli RS et al..  2020.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.

Gilvary C, Elkhader J, Madhukar N, Henchcliffe C, Goncalves MD, Elemento O.  2020.  A machine learning and network framework to discover new indications for small molecules.. PLoS Comput Biol. 16(8):e1008098.

Gilvary C, Elkhader J, Madhukar N, Henchcliffe C, Goncalves MD, Elemento O.  2020.  A machine learning and network framework to discover new indications for small molecules.. PLoS Comput Biol. 16(8):e1008098.